Agenus Inc (NASDAQ:AGEN)’s share price shot up 0% on Friday . The company traded as high as $6.02 and last traded at $5.84. 4,310,726 shares traded hands during mid-day trading, an increase of 150% from the average session volume of 1,726,878 shares. The stock had previously closed at $5.84.
A number of research firms have recently weighed in on AGEN. Zacks Investment Research raised shares of Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Tuesday, January 9th. BidaskClub raised shares of Agenus from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, ValuEngine raised shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Agenus has an average rating of “Buy” and an average price target of $5.81.
The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39. The company has a market cap of $583.24, a PE ratio of -4.99 and a beta of 1.50.
Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The business had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.30 million. The business’s quarterly revenue was up 48.2% compared to the same quarter last year. equities research analysts forecast that Agenus Inc will post -1.16 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC acquired a new position in Agenus during the fourth quarter worth $124,000. Raymond James & Associates acquired a new position in Agenus during the fourth quarter worth $130,000. Cubist Systematic Strategies LLC acquired a new position in Agenus during the third quarter worth $134,000. Voya Investment Management LLC increased its position in Agenus by 18.5% during the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,381 shares during the last quarter. Finally, North Star Asset Management Inc. acquired a new position in Agenus during the fourth quarter worth $222,000. 36.69% of the stock is currently owned by hedge funds and other institutional investors.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.